Followers | 29 |
Posts | 6477 |
Boards Moderated | 0 |
Alias Born | 05/17/2011 |
Thursday, April 19, 2018 3:15:52 PM
Recent RGNX News
- REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD • PR Newswire (US) • 03/28/2024 11:05:00 AM
- REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days • PR Newswire (US) • 03/27/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 12:00:31 PM
- REGENXBIO to Participate in Upcoming Investor Conferences • PR Newswire (US) • 03/11/2024 11:05:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/08/2024 11:09:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 11:05:43 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 03/07/2024 11:03:26 AM
- REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants • PR Newswire (US) • 03/07/2024 04:20:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/06/2024 09:23:14 PM
- REGENXBIO Announces Proposed Public Offering of Common Stock • PR Newswire (US) • 03/06/2024 09:10:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 09:26:29 PM
- REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL • PR Newswire (US) • 03/05/2024 12:05:00 PM
- REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial • PR Newswire (US) • 02/29/2024 09:57:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/27/2024 09:54:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:10:25 PM
- REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights • PR Newswire (US) • 02/27/2024 09:05:00 PM
- REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights • PR Newswire (US) • 02/21/2024 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 11:28:44 PM
- REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint • PR Newswire (US) • 02/07/2024 04:40:00 PM
- REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial • PR Newswire (US) • 02/07/2024 12:05:00 PM
- REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024 • PR Newswire (US) • 01/31/2024 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 11:39:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/16/2024 09:22:35 PM
- REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery • PR Newswire (US) • 01/16/2024 07:47:00 PM
- REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting • PR Newswire (US) • 01/10/2024 12:05:00 PM
FEATURED Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • Apr 17, 2024 8:00 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM
Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million • BLEG • Apr 16, 2024 8:30 AM